Alembic Pharmaceuticals Limited (APLLTD.NS) Bundle
From its founding in 1907 in Vadodara to a modern multinational footprint, Alembic Pharmaceuticals Limited blends legacy and ambition-employing 16,571 people (as of March 31, 2025), investing ₹530 crore in R&D (FY 2025) and securing multiple US FDA approvals between 2024-2025 to reinforce its global generics and formulations presence; guided by a mission centered on innovation, commitment and trust and a vision that embeds environmental stewardship (targeting a 63% reduction in greenhouse gas emissions by FY 2034 and water neutrality by 2027), Alembic's core values-Integrity, Quality, Innovation (allocating about 12% of annual revenue to R&D), Customer Focus (with a reported 92% customer satisfaction) and Employee Empowerment (over 50,000 training hours in 2024)-drive initiatives like Swasthya Setu that deliver free care to roughly 10,000 patients annually while the company advances therapies across cardiology, dermatology, diabetes, ophthalmology and infectious diseases for both domestic and international markets
Alembic Pharmaceuticals Limited (APLLTD.NS) - Intro
Overview- Founded: 1907; Headquarters: Vadodara, Gujarat, India
- Business scope: Development, manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished formulations
- Therapeutic focus areas:
- Cardiology
- Dermatology
- Diabetes
- Ophthalmology
- Infectious diseases
- Markets served: Domestic India and multiple international markets including regulated markets (US, EU) and emerging markets
| Metric | Value / As of |
|---|---|
| Employees | 16,571 (March 31, 2025) |
| R&D Investment | ₹530 crore (FY ended March 31, 2025) |
| Regulatory approvals (selected) | Multiple US FDA final and tentative approvals (2024-2025) |
| GHG reduction target | Reduce greenhouse gas emissions by 63% by FY 2034 |
| Water target | Achieve water neutrality by 2027 |
- Deliver high-quality, affordable medicines that improve patient outcomes globally.
- Continuously innovate across APIs and formulations while maintaining regulatory compliance and manufacturing excellence.
- Be a globally respected, science-led pharmaceutical company recognized for product quality, patient-centric solutions, and sustainable operations.
- Expand presence in regulated markets and specialty therapeutic segments while driving long-term value for stakeholders.
- Integrity - adherence to ethical standards across R&D, manufacturing and commercialization.
- Quality - uncompromising focus on product quality and regulatory compliance.
- Innovation - sustained investment in R&D (₹530 crore in FY2025) to develop generics, niche formulations and APIs.
- Customer focus - ensuring accessibility and affordability for healthcare providers and patients.
- Sustainability - measurable commitments to reduce emissions and achieve water neutrality.
- People-first - investing in workforce capabilities and safety (16,571 employees as of March 31, 2025).
- Regulatory and launch execution: Secured multiple US FDA approvals in 2024-2025 to strengthen the US generics portfolio and pipeline.
- R&D-led growth: Continued CAPEX and R&D spend (₹530 crore in FY2025) to support complex generics, differentiated formulations and API development.
- Operational excellence: Scale manufacturing capacity to serve both regulated and emerging markets while maintaining cost competitiveness.
- Sustainability integration: Aligning operational improvements with targets - 63% GHG reduction by FY2034 and water neutrality by 2027.
- Multiple final and tentative approvals from the US FDA for generic medicines across different dosage forms (2024-2025).
- Ongoing dossier filings and lifecycle management initiatives to convert approvals into commercial launches in primary markets.
| Area | Why it matters |
|---|---|
| R&D spend (₹530 crore) | Signals pipeline investment and potential for differentiated products and margin improvement |
| Regulatory approvals | Directly tied to revenue growth opportunities in high-value regulated markets |
| Sustainability targets | Mitigates long-term operational risks and aligns with investor ESG expectations |
| Workforce size | Supports scale-up capability across manufacturing, regulatory and commercial functions |
Alembic Pharmaceuticals Limited (APLLTD.NS) - Overview
Alembic Pharmaceuticals Limited's mission is to improve healthcare with innovation, commitment, and trust. This mission drives strategic priorities across R&D, manufacturing, regulatory affairs, and branded formulations, and informs the company's interactions with patients, prescribers, regulators, and investors.- Innovation - focused investment in R&D, new formulations, ANDA filings, and biologics/complex generics development.
- Commitment - consistent manufacturing scale-up, capacity expansions, and supply-chain resilience for domestic and export markets.
- Trust - quality systems, regulatory compliance, and ethical practices to maintain long-term partnerships with healthcare professionals and distributors.
| Metric / Area | Value / Note |
|---|---|
| Reported Consolidated Revenue (FY) | ₹4,300-4,500 crore (latest fiscal year reported) |
| Reported Consolidated PAT (FY) | ≈₹350 crore (latest fiscal year reported) |
| R&D Spend | Typically 3-5% of sales; ongoing investment in product development and ANDA/INN filings |
| Domestic Branded Portfolio | Wide portfolio across cardiology, dermatology, pain management, and speciality segments |
| Exports & Global Markets | Significant exports to regulated markets (US, Europe) via generics and APIs; growing share of international revenues |
| Manufacturing Footprint | Multiple WHO-GMP / global regulatory-compliant facilities for formulations and APIs |
| Employee Base | Several thousand employees across India and global operations |
- Pipeline expansion - accelerating ANDA filings and biosimilar/complex generic development to broaden therapeutic reach.
- Capacity augmentation - investments in manufacturing lines and API units to meet rising demand domestically and internationally.
- Quality & compliance - strengthening regulatory submissions and post-approval surveillance to build trust in markets governed by stringent regulators.
- Commercial focus - deepening branded formulations presence in India while scaling global generics distribution.
- Patients - improved access to affordable and effective medicines through branded and generic offerings.
- Healthcare providers - reliable supply and scientifically supported products for therapeutic decisions.
- Investors - revenue diversification across branded domestic business and export generics, with margin sensitivity to R&D and regulatory investments.
- Employees & partners - clear ethical standards and innovation-led growth opportunities.
Alembic Pharmaceuticals Limited (APLLTD.NS) Mission Statement
Alembic Pharmaceuticals Limited (APLLTD.NS) frames its mission around delivering high-quality, affordable healthcare while embedding social responsibility and environmental stewardship into every facet of its business. The company's mission aligns scientific innovation, manufacturing excellence, and community commitment to create long-term value for patients, employees, investors and society. Vision Statement Alembic's vision is guided by perseverance and an unflinching sense of duty towards the community and environment. This vision manifests through measurable sustainability commitments and operational practices designed to reduce environmental impact while ensuring reliable access to medicines.- Integrate sustainability into core business operations to create long-term stakeholder value.
- Minimize greenhouse gas (GHG) emissions, hazardous and non-hazardous waste, and overall water footprint.
- Conserve water resources and participate in groundwater recharge and restoration initiatives.
- Accept responsibility for climate change impacts and protect local water sources supporting host communities.
- Responsible manufacturing: Continuous improvement in process efficiencies to lower emissions and waste intensity.
- Water stewardship: Technologies and projects aimed at reducing freshwater withdrawal, increasing recycling and recharging groundwater.
- Community engagement: Health camps, local water-conservation programs and livelihood initiatives tied to manufacturing hubs.
- Regulatory and quality excellence: Sustained investment in compliant, world-class manufacturing facilities and robust quality systems.
| Metric | Reported Value (latest disclosed year) |
|---|---|
| Consolidated Revenue | ₹3,843 crore |
| Net Profit (Consolidated) | ₹366 crore |
| R&D Spend (% of revenue) | ~6% (approx. ₹230 crore) |
| Scope 1 & 2 GHG Emissions | ~25,000 tCO2e |
| Water Withdrawal (total) | ~1.2 million m³ |
| Total Hazardous + Non-hazardous Waste | ~1,800 tonnes |
| Emissions reduction target | ~30% by 2030 (baseline year disclosed in sustainability report) |
| Net-zero ambition | Targeted by 2050 |
- Integrity: Adherence to ethical standards across research, manufacturing and commercial conduct.
- Quality: Patient safety and product efficacy as non-negotiable priorities.
- Accountability: Measurable targets for environmental performance and social impact.
- Innovation: Investing in R&D to advance therapies and improve process sustainability.
- Community-first approach: Local engagement programs focused on health, water and livelihoods.
- Water conservation: Implementation of recycling systems and rainwater harvesting to reduce freshwater intake and recharge aquifers.
- Energy transition: Incremental shifts toward renewables and energy-efficient process upgrades to lower Scope 2 emissions.
- Waste minimization: Process optimization and safe disposal/treatment practices to cut hazardous and non-hazardous waste generation.
- Reporting and transparency: Periodic sustainability disclosures aligned with recognized frameworks and stakeholder expectations.
| Stakeholder | Value Delivered | Representative Metric |
|---|---|---|
| Patients | Affordable, quality medicines and expanded access | Number of registered formulations and market reach (domestic & export) |
| Investors | Long-term value through sustainable operational efficiencies | Revenue growth, margin improvement, and consistent dividend policy |
| Communities | Water projects, health camps, livelihood support | Groundwater recharge volumes and community programs supported |
| Environment | Lowered emissions and reduced waste intensity | Emission and waste reduction % vs. baseline year |
Alembic Pharmaceuticals Limited (APLLTD.NS) - Vision Statement
Alembic Pharmaceuticals Limited envisions becoming a globally trusted pharmaceutical innovator that delivers high-quality, affordable therapies while driving sustainable growth and societal well-being. The vision is anchored in measurable commitments across R&D intensity, product quality, stakeholder trust, workforce development, and community health outreach.- Integrity: Uphold honesty, transparency and regulatory compliance across manufacturing, clinical development, and commercial operations to maintain stakeholder confidence.
- Quality: Commit to rigorous quality systems that ensure patient safety and product efficacy across branded formulations, specialty APIs, and international markets.
- Innovation: Allocate disciplined investment in research and development to generate novel therapies and lifecycle enhancements.
- Customer focus: Prioritize patient and physician needs to sustain high satisfaction and long-term relationships.
- Employee empowerment: Invest in training, leadership development and a performance culture to enable execution of strategic priorities.
- Social responsibility: Scale community health initiatives and access programs that deliver measurable public health impact.
| Metric | Reported / Target Value | Notes |
|---|---|---|
| R&D intensity | 12% of annual revenue | Ongoing investment across discovery, development & regulatory submissions |
| Customer satisfaction | 92% | Latest company-wide survey covering physicians, distributors and end patients |
| Employee training (2024) | 50,000+ hours | Focus: technical skills, GMP, leadership and compliance |
| Community health reach (Swasthya Setu) | ~10,000 patients annually | Free medical camps and outreach programs |
| Estimated annual revenue (illustrative) | INR 3,200 crore (≈ USD 390M) | Used to contextualize R&D spend; refer to audited filings for exact figures |
| Estimated R&D spend (12% of revenue) | INR 384 crore (≈ USD 47M) | Illustrative calculation: 12% × INR 3,200 crore |
- Scale innovation pipelines by increasing translational research collaborations and filing prioritized regulatory dossiers in key markets.
- Enhance manufacturing excellence and supply-chain resilience to sustain product quality and meet global demand.
- Deepen customer engagement programs to maintain and improve the 92% satisfaction benchmark.
- Expand workforce capability through targeted training-building on the 50,000+ hours delivered in 2024.
- Grow social impact initiatives like Swasthya Setu to increase annual beneficiaries beyond 10,000 patients.
Alembic Pharmaceuticals Limited (APLLTD.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.